Format

Send to

Choose Destination
See comment in PubMed Commons below
Ophthalmology. 2008 Dec;115(12):2253-8. doi: 10.1016/j.ophtha.2008.07.003. Epub 2008 Oct 29.

Clinical spectrum of diffuse infiltrating retinoblastoma in 34 consecutive eyes.

Author information

1
Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. carol.shields@shieldsoncology.com

Abstract

PURPOSE:

To evaluate the clinical features and management of diffuse infiltrating retinoblastoma.

DESIGN:

Retrospective case series.

PARTICIPANTS:

Thirty-four eyes in 32 patients.

METHODS:

The patients' records were reviewed for patient and tumor features, ocular management, histopathologic findings, and patient survival.

MAIN OUTCOME MEASURES:

Clinical features, tumor management, and patient survival.

RESULTS:

Of 1507 patients with retinoblastoma, only 32 (2%) were classified with diffuse infiltrating retinoblastoma. The mean age at diagnosis was 4 years (range 1.5-16 years). The referring diagnoses included retinoblastoma (26 eyes, 76%), uveitis (3, 9%), Coats disease (1, 3%), trauma (1, 3%), and unspecified retinal problem (3, 9%). The anterior segment displayed tumor seeds on the corneal endothelium (8, 24%), cornea stromal edema (3, 9%), pseudohypopyon (11, 32%), hyphema (3, 9%), iris neovascularization (17, 50%), and iris tumor nodules (6, 18%). The posterior segment revealed extensive ill-defined retinoblastoma infiltrating the retina for a mean basal diameter of 20 mm and overall flat growth, sometimes with undulating retinal thickening. Overlying extensive vitreous tumor seeds (31, 91%) and vitreous hemorrhage (8, 24%) were noted. Calcification was present on ultrasonography (27/34, 79%) and computed tomography (8/9, 89%). Enucleation was performed for all 34 eyes, and there were no cases of metastases at 47 months follow-up.

CONCLUSIONS:

Diffuse infiltrating retinoblastoma can masquerade as uveitis or unexplained hyphema or keratic precipitates. Suspicion for retinoblastoma is important.

FINANCIAL DISCLOSURE(S):

The authors have no proprietary or commercial interest in any materials discussed in this article.

PMID:
18962920
DOI:
10.1016/j.ophtha.2008.07.003
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center